Healthcare Industry News: RNAi therapeutics
News Release - May 30, 2007
Intradigm Announces Addition of Samuel Zalipsky to Management TeamPALO ALTO, Calif., May 30 (HSMN NewsFeed) -- Intradigm Corporation, a leading developer of targeted and effective RNA interference (RNAi) therapeutics, today announced the appointment of Samuel Zalipsky, Ph.D., as vice president, technology development. Dr. Zalipsky brings more than 20 years of experience in the pharmaceutical and biotechnology industry and offers significant expertise in areas critical to Intradigm's growth.
Dr. Zalipsky comes to Intradigm following an eight-year tenure with ALZA Corporation, a member of the Johnson & Johnson family of companies, during which he established himself as a leading expert on drug delivery systems. His broad drug delivery expertise spans several important areas including chemistry of peptides, polymers for bio-medical application, bioconjugates with drugs, peptides/proteins, saccharides, lipids/liposomes, and nanoparticles. He is widely regarded as an active researcher and inventor, particularly in the areas of macromolecular and nanoparticular carrier-mediated delivery.
At ALZA, Dr. Zalipsky established and managed programs focused on delivery of biopharmaceuticals, PEGylated proteins, and targeted delivery of liposomes. Prior to his work with ALZA, he held key scientific positions with SEQUUS Pharmaceuticals and Enzon Inc., while also serving as a visiting associate professor in the chemistry department of Rutgers University. In his new role, Dr. Zalipsky will spearhead the continued development of Intradigm's proprietary nanoparticle-based RNAi delivery technology, as well as its novel RNAi therapeutic formulations. He will also be responsible for overseeing the company's work in the areas of new technology development and new technology in-licensing.
"While Samuel possesses impressive experience in the biotechnology and pharmaceutical industry, it is the relevance of his expertise as it relates to Intradigm's RNAi drug delivery focus that makes him such an ideal addition to our team," said Mohammad Azab, M.D., president and chief executive officer of Intradigm. "We are very happy to welcome Samuel to Intradigm and look forward to the critical contributions he will make to the company and our efforts to bring innovative RNAi therapeutics to the market."
Intradigm is a private biotechnology company dedicated to the development of targeted and effective RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in the development and delivery of RNAi molecules serves as the foundation of Intradigm's drug development platform. In particular, the company's novel and proprietary RNAi Nanoplex(TM) delivery technology is unique in its ability to allow the targeted delivery of RNAi therapeutics to specific tissues though systemic administration.
At present, Intradigm is working to build a high-value internal pipeline of RNAi oncology therapeutics, and is actively advancing its lead internal drug candidate, ICS-283, for a variety of cancer indications. The company is also establishing collaborative relationships with pharmaceutical and biotechnology companies through which Intradigm's advanced RNAi delivery technology may be applied to a broad range of therapeutic targets. For more information on Intradigm, please visit http://www.intradigm.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.